Edmund Dunn - 03 Jun 2025 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role: Principal Accounting Officer
Signature: /s/ Phil Nickson, Attorney-in-Fact
Issuer symbol: GLUE
Transactions as of: 03 Jun 2025
Net transactions value: -$9,174
Form type: 4
Filing time: 04 Jun 2025, 16:15:08 UTC
Previous filing: 06 Jan 2025
Next filing: 05 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Dunn Edmund	Principal Accounting Officer	MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON	/s/ Phil Nickson, Attorney-in-Fact	04 Jun 2025	0001989401

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GLUE	Common Stock	Sale	$9,174	-2,062	-8%	$4.45	23,732	03 Jun 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.34 to $4.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.34 to $4.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.